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Abstract  Chronic  immunosuppression  is  a  known  risk  factor  for  tuberculosis.  Our  aim  was  to
reach a  consensus  on  screening  and  prevention  of  tuberculosis  in  patients  with  immune  mediated
inﬂammatory  diseases  who  are  candidates  to  biologic  therapy.
Methods:  Critical  appraisal  of  the  literature  and  expert  opinion  on  immunosuppressive  therapies
and risk  of  tuberculosis.
Results  and  conclusion: The  currently  recommended  method  for  screening  is  the  tuberculin  skin
test and  the  interferon  gamma  assay,  after  exclusion  of  active  tuberculosis.  Positively  screened
patients should  be  treated  for  latent  tuberculosis  infection.  Patients  may  start  biological  ther-ong  as  they  are  strictly  adhering  to  and  tolerating  their  preventivediseases apy after  1--2  months,  as  l
regimen.
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reserved.
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Rastreio  da  tuberculose  em  portadores  de  doenc¸as inﬂamatórias  imunomediadas
candidatos  a  terapêutica  biológica
Resumo  A  imunossupressão  crónica  é  um  reconhecido  factor  de  risco  para  a  tuberculose.  O
nosso objectivo  foi  o  de  obter  um  consenso  para  o  rastreio  e  prevenc¸ão  da  tuberculose  em
portadores  de  doenc¸as  inﬂamatórias  imunomediadas  candidatos  a  terapêutica  biológica.
Métodos: Revisão  crítica  da  literatura  e  opinião  de  peritos  acerca  das  terapêuticas  imunossu-
pressoras  e  risco  de  tuberculose.
Resultados  e  conclusão: O  método  actualmente  recomendado  para  o  rastreio  é  o  teste  cutâ-
neo da  tuberculina  e  o  doseamento  do  interferão  gama,  após  exclusão  da  tuberculose  activa.
Doentes com  rastreio  positivo  devem  receber  tratamento  para  a  tuberculose  latente.  Estes
doentes podem  iniciar  a  terapêutica  biológica  após  1  a  2  meses,  desde  que  a  sua  adesão  seja
rigorosa e  apresentem  boa  tolerância  à  terapêutica  proﬁlática.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
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Introduction
In  populations  with  high  incidence  of  tuberculosis  (TB),
there  have  been  an  increased  number  of  TB  cases  reported
in  patients  treated  with  tumor  necrosis  factor  antagonists
(anti-TNF).1 In  fact,  the  relative  risk  (RR)  of  developing  TB  is
1.6--25.2  times  higher  in  Rheumatoid  Arthritis  (RA)  patients
under  anti-TNF  therapy  than  in  RA  patients  treated  with
conventional  immunosuppressive  therapy,  depending  on  the
clinical  setting  and  the  anti-TNF  used.1--7
Active  TB  in  the  context  of  anti-TNF  therapy  usually
results  from  the  reactivation  of  a  latent  infection,  shortly
after  the  beginning  of  the  treatment.5,8 TB  often  presents
an  atypical  behavior,  which  may  pose  difﬁculties  to  the
diagnosis.9 In  countries  with  high  incidence  of  TB,  cases
caused  by  new  infection  are  also  particularly  frequent.
TNF  is  fundamental  for  the  immunological  defence  against
Mycobacterium  tuberculosis, especially  in  the  formation  and
maintenance  of  granulomas.  Animal  models  conﬁrmed  that
it  is  possible  to  reactivate  TB  after  administering  anti-TNF
antibodies.10
Besides  anti-TNFs,  other  biological  agents  were  approved
for  immune  mediated  inﬂammatory  disease’s  treatment.
Data  about  the  risk  of  developing  TB  infection  in  patients
treated  with  these  other  agents  are  scarce.  Even  though  this
risk  might  be  lower  for  some  of  the  biological  agents  that
do  not  interfere  with  TNF  until  more  data  is  available  this
group  assumed  that  this  position  paper  should  be  applied  to
all  biological  treatments.
Preventive  chemotherapy  can  signiﬁcantly  reduce  the
incidence  of  active  TB  in  individuals  with  latent  infec-
tion,  identiﬁed  by  positive  tuberculin  skin  test  (TST)  or
interferon- release  assay  (IGRA).11
The  currently  available  evidence  about  the  best  man-
agement  to  prevent  TB  in  patients  receiving  biological
therapy  is  limited.  In  this  position  paper  on  the  screening
and  prevention  of  TB  in  patients  treated  with  biologi-
cal  therapy,  delegates  from  the  Tuberculosis  Committee
(TC)  of  the  Portuguese  Pulmonology  Society  (SPP),  the
Rheumatoid  Arthritis  Study  Group  (GEAR)  of  the  Portuguese
Society  of  Rheumatology  (SPR),  the  Portuguese  Society  of
Dermatology  and  Venereology  (SPDV)  and  the  Portuguese
Society  of  Gastroenterology  (SPG),  have  revised  and  updated
P
s
aecommendations  that  had  been  previously  developed  by
he  GEAR  -- SPR  and  by  the  TC  -- SPP,  ﬁrst  published  in  200612
nd  latter  updated  in  2008.13
The  main  objective  of  this  position  paper  is  to  contribute
or  the  reduction  of  the  number  of  cases  of  reactivated  TB
nd  new  TB  infections  in  patients  with  immune  mediated
nﬂammatory  diseases  who  are  candidates  for  treatment
ith  biological  therapy  in  Portugal.  An  additional  objective
s  to  standardize  the  procedures  used  to  screen  and  prevent
B  in  the  initial  assessment  of  these  patients,  preferably  at
isease  onset,  before  the  beginning  of  any  immunosuppress-
nt  therapy.
ecommendations
ho  should  be  screened?
ll  patients  with  immune  mediated  inﬂammatory  diseases
ho  are  candidates  for  the  use  of  biological  therapy  should
e  screened  for  latent  TB  infection  (LTBI)  prior  to  starting
herapy  (Evidence  level  C).
Patients  eligible  for  anti-TNF  therapy  have  an  increased
isk  of  developing  TB  upon  starting  this  treatment.  TB  in
his  setting  can  present  with  severe,  atypical  and  life-
hreatening  manifestations.  This  risk  exists  not  only  due  to
he  biological  importance  of  TNF  in  the  initiation  and  main-
enance  of  the  response  against  M.  tuberculosis, but  also
ecause  the  underlying  diseases  (e.g.  RA)  and  concomitant
reatments  (e.g.  steroid  therapy)  increase  the  risk  of  TB  per
e.14--18 Most  of  the  active  TB  cases  in  patients  treated  with
nti-TNF  are  due  to  reactivation  of  LTBI.  It  is  well  known
hat  screening  for  LTBI  before  starting  anti-TNF  therapy  is
ffective  in  preventing  reactivation  of  TB.17 Therefore,  all
ational  guidelines  recommend  the  exclusion  of  active  TB
isease  and  LTBI  in  patients  in  whom  biological  therapy  is
onsidered.19--21
hen  to  screen?atients  with  immune  mediated  inﬂammatory  diseases
hould  be  screened  for  TB  before  starting  biologic  treatment
nd  ideally  when  the  disease  is  diagnosed  (Evidence  level  C).
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Any  candidate  to  biological  therapy  should  be  screened
or  the  presence  of  speciﬁc  immune  response  to  M.  tuber-
ulosis  (including  TST  and  IGRA)  before  starting  these  drugs
nd  ideally  when  the  immune  mediated  inﬂammatory  dis-
ase  is  diagnosed,  except  in  patients  with  mild  forms  of
soriasis,  treated  with  topical  drugs.19--21
It  has  been  shown  that  certain  diseases,  such  as  RA,  as
ell  as  chronic  immunosuppressive  therapy,  such  as  corti-
osteroids  (>15  mg/day  for  more  than  2  weeks)  increase  the
isk  of  TB.  In  addition,  it  is  also  well  known  that  immuno-
uppressive  therapy  compromises  the  sensitivity  of  the  TST
nd  IGRA,  this  being  especially  true  for  TST.16,18,22--25 There-
ore,  it  is  highly  desirable  that  the  ﬁrst  screen  for  TB  should
e  done  at  the  moment  of  diagnosis,  before  any  kind  of
mmunosuppressive  treatment  or  phototherapy  is  started.
hich  tests  should  we  use?
fter  exclusion  of  active  TB,  LTBI  should  be  screened  with
ST  and  IGRA  (Evidence  level  C  and  D).
In  the  light  of  current  knowledge,  and  in  the  absence  of
 gold  standard  test  for  LTBI  diagnosis,19 the  screening  pro-
ess  for  LTBI  requires  a  combination  of  a  detailed  medical
istory  (which  should  include  ethnicity,  country  of  birth,  his-
ory  of  or  recent  exposure  to  TB,  previous  TB  and  respective
reatment,  co-morbidities  associated  with  increased  risk  of
B,  professional  activities  with  increased  risk  of  exposure
o  TB),  travel  to  endemic  areas,  chest  radiograph  (search-
ng  for  changes  indicative  of  active  or  residual  previous  TB)
nd  tests  for  immunological  memory  against  M.  tuberculo-
is  (TST  and  IGRA).19 In  erythrodermic  psoriasis  TST  may  be
mpossible  to  perform,  reinforcing  the  need  of  IGRA  in  these
ases.
The  sensitivity  of  both  tests  may  be  compromised  in
atients  receiving  immunosuppressive  therapy,  although
ublished  evidence  suggests  that  IGRA  has  a  higher  sen-
itivity  than  TST  in  patients  with  immune  mediated
nﬂammatory  diseases,  even  after  starting  immunosuppress-
ve  therapy.26--30
Currently,  different  guidelines  are  adopted  regarding  the
se  of  TST  and  IGRA,  reﬂecting  the  difﬁculty  of  choosing  the
est  strategy.19,24,31--33 Over-treatment,  implying  the  risk  of
rug  toxicity  due  to  a  false-positive  screening  and  under-
reatment  due  to  a  false-negative  screening  are  the  main
oncerns.
Since  the  increase  in  sensitivity  and  speciﬁcity  provided
y  IGRA  in  different  studies  is  controversial  and  their  pos-
tive  and  negative  predictive  values  are  yet  to  be  deﬁned,
he  role  of  IGRA  is  still  under  investigation.  In  this  sense,
GRA  cannot  yet  be  used  as  a  single  test  for  immunological
emory  to  M.  tuberculosis. Thus,  currently  it  is  prudent  to
se  both  TST  and  IGRA  in  order  to  maximize  sensitivity.19,24,31
Since  patients  may  have  false  negative  TST  due  to
mmunosuppression,  a  two  step  approach  is  advised----repeat
ST  1--3  weeks  after  the  initial  negative  screening.
ow  to  exclude  active  tuberculosis  in  patients
ith Crohn’s  disease?
cid  fast  bacilli  smear  and  culture  should  be  performed  in
ndoscopic  biopsies  (Evidence  level  C).
r
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The  distinction  between  Crohn’s  disease  and  intesti-
al  TB  is  a  diagnostic  challenge,  as  they  present  similar
linical,  radiological,  endoscopic  and  histological  fea-
ures.Investigation  of  patients  with  suspected  Crohn’s
isease  should  always  include  differential  diagnosis  with
ntestinal  TB.  Acid  fast  bacilli  smear  and  culture  are  warr-
nted  in  pathological  examination  of  endoscopic  biopsies.
ther  tests  such  as  nucleic  acid  ampliﬁcation,  immunohis-
ochemistry  or  in  situ  hybridization  are  promising  techniques
hat  have  been  evaluated  in  some  studies,  but  they  are  not
idely  available  and  require  further  validation.34--51
ow  to  interpret  the  tuberculin  skin  test?
ST  is  considered  positive  if  induration  is  ≥5  mm  in  previ-
usly  immunosuppressed  patients  and  if  ≥10  mm  in  patients
ot  previously  exposed  to  immunosuppressors  (Evidence
evel  D).
In  order  to  increase  the  sensitivity  of  TST  (at  the  expense
f  lower  speciﬁcity)  different  guidelines  recommend,  in  the
mmunocompromised  population,  an  induration  of  ≥5  mm  to
e  the  cut-off  for  a  positive  TST.19,21,52,53
The  Tuberculosis  Network  European  Trials  Group  (TBNET)
ecommends  a  cut-off  value  of  10  mm,  stating  that  the  loss
f  sensitivity  to  detect  infection  by  increasing  the  cut-off
rom  5  to  10  mm  is  marginal,  while  the  gain  in  speciﬁcity  is
ubstantial.19 Taking  this  into  consideration,  TBNET  suggests
hat  a  TST  ≥  10  mm  should  lead  to  LTBI  treatment,  with-
ut  requiring  IGRA  conﬁrmation.  This  evidence  is  based  on
esults  of  non-controlled  and  non-randomized  trials  and  on
bservational  studies.
According  to  the  Portuguese  clinical  practice,  patients
ith  immune  mediated  inﬂammatory  diseases,  who  are  can-
idates  for  anti-TNF  therapy,  should  undergo  a  TST:  the
est  is  considered  positive  in  previously  immunosuppressed
atients  if  the  induration  is  ≥5  mm  and  in  patients  not  pre-
iously  exposed  to  immunosuppressors  if  the  induration  is
10  mm.
ho  should  start  latent  tuberculosis  infection
reatment?
atients  with  epidemiological  risk  factors  for  TB  (history  of
xposure  to  TB,  previous  TB,  emigrants  from  high  TB  preva-
ence  areas,  residents  in  high  incidence  areas,  co  morbidities
ssociated  with  increased  risk  of  TB,  professional  activities
ith  increased  risk  of  exposure  to  TB,  travel  to  endemic
reas),  or  chest  X-ray  sequelae  of  untreated  previous  TB,  or
ositive  TST  and/or  IGRA,  should  start  LTBI  treatment,  after
xclusion  of  active  TB  (Evidence  level  C  and  D).
Whenever  there  is  evidence  of  exposure  to  TB  (regardless
he  results  of  the  screening  and  after  exclusion  of  active  TB)
r  LTBI  (positive  TST  and/or  IGRA  or  changes  in  chest  radio-
raph  suggestive  of  previous  untreated  TB),  after  exclusion
f  active  TB,  preventive  treatment  should  be  offered  before
nitiating  biological  therapy,  as  these  patients  have  a  high
isk  of  progression  to  disease.19,21,54--57
Due  to  the  risk  of  serious  forms  of  disease,  treatment
ust  be  offered  to  candidates  for  biological  therapy  regard-
ess  of  age  and  presumed  date  of  infection.
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Which  latent  tuberculosis  infection  treatment
regimen should  be  used?
Isoniazid  for  9  months  (Evidence  level  C  and  D).
Several  therapeutic  strategies  have  been  proposed.
Isoniazid  is  classically  recommended  as  this  drug  in  immuno-
compromised  patients  has  proven  to  be  effective  (data
derived  from  multiple  studies  in  HIV  patients).58--60 Isoniazid
for  a  period  of  9  months  is  the  most  commonly  used  regimen
and  has  an  estimated  efﬁcacy  of  around  90%.  This  regimen
is  recommended  by  the  American  Thoracic  Society  (ATS)61
and  Canadian  Tuberculosis  Standards,62 while  the  6  months
regimen,  in  which  effectiveness  varies  between  65  and  69%,
is  proposed  by  the  National  Institute  for  Health  and  Clinical
Excellence  (NICE).63
TBNET  recommends  treatment  with  isoniazid  for  9--12
months  or  isoniazid  and  rifampicin  for  3  months  (3HR).19
However,  the  later  is  associated  with  a  lower  efﬁcacy
(around  60%).  Some  studies  indicate  that  4 months  of
rifampicin  (4R)  are  at  least  as  effective  as  3HR  and  this
regime  has  the  advantage  of  being  better  accepted  by
patients,  having  fewer  adverse  effects  when  compared  with
regimens  based  on  isoniazid  and  is  associated  with  a  lower
cost  to  the  health  system.64--68 These  are  very  relevant
advantages  but  effectiveness  remains  uncertain,  as  this  reg-
imen  has  not  yet  been  tested  extensively  in  randomized
trials.
In  the  light  of  current  knowledge,  treatment  with  isoni-
azid  for  9  months  is  the  most  consensual  option.19,59,60 One
month  is  deﬁned  as  the  minimum  LTBI  treatment  duration
before  starting  biological  drugs.19 This  recommendation  is
based  on  expert  opinion.
Evaluation  of  the  risk  for  toxicity  due  to  latent
tuberculosis infection  treatment
Patient  education,  clinical  monitoring,  baseline  and  monthly
laboratory  testing  of  liver  enzymes  (Evidence  level  C  and  D).
Given  the  high  risk  of  TB  in  patients  starting  anti-TNF,
the  risk  of  age-related  hepatotoxicity69 should  not  prevent
patients  from  receiving  treatment  for  LTBI.  In  addition  to
liver  toxicity,  isoniazid  is  associated  with  toxicity  to  the
nervous  system.70 Vitamin  B6  reduces  central  and  periph-
eral  effects  of  isoniazid  and  should  be  given  to  individuals
with  a  history  of  alcoholism,  diabetes,  pregnant,  postpar-
tum,  infants,  malnourished,  HIV-positive,  people  with  active
liver  disease,  cancer  or  history  of  pre-existing  peripheral
neuropathy.71
In  case  of  choosing  rifampicin-based  regimens,  interac-
tions  with  other  drugs  should  be  considered,  since  this  drug
is  a  potent  inducer  of  CYP450.72
Besides  patient  education  and  clinical  monitoring,  base-
line  and  monthly  (or  biweekly)  laboratory  testing  of  liver
enzymes  is  recommended  for  people  older  than  35  years,
6
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hronic  alcohol  abusers,  HIV-infected  persons,  females  dur-
ng  pregnancy  and  within  3  months  after  delivery  and  for
hose  with  chronic  liver  disease  or  taking  potentially  hep-
totoxic  concomitant  medications.  Transient  transaminase
levations  are  common  and  may  reﬂect  the  process  of
epatic  adaptation.  However,  isoniazid  and/or  rifampicin
hould  be  withheld  as  recommended  if  the  serum  transam-
nase  level  is  higher  than  three  times  the  upper  limit  of
ormal  in  a  symptomatic  patient  or  ﬁve  times  the  upper
imit  of  normal  in  the  absence  of  symptoms.60,61
A  change  of  the  therapeutic  regimen  for  a  less  hepato-
oxic  one  (as  4R,  at  the  expense  of  effectiveness)  should
e  considered  when  serious  hepatotoxicity  is  limiting  LTBI
reatment  with  isoniazid.
ow  should  follow  up  be  performed?
atients  should  be  re-screened  for  LTBI  if  the  previous  screen
ad  been  negative  and  the  patient  had  not  started  biologi-
als,  to  exclude  possible  infection  in  the  meantime  (in  the
bsence  of  a  known  contact  with  a  TB  patient,  the  screen
ould  be  valuable  for  6  months).  In  the  event  of  contact
ith  active  TB,  TB  screening  should  be  promptly  performed
nd  in  the  absence  of  disease  and  LTBI,  chemoprophylaxis
hould  be  guaranteed.19
Annual  testing  is  recommended  for  patients,  who  live,
ravel  or  work  in  environments  where  TB  exposure  is  likely,
hile  they  continue  treatment  with  biologic  agents.  Patients
ho  tested  positive  for  TST  and  IGRA  should  only  be  moni-
ored  for  clinical  signs  of  TB.
ummary
.  All  candidates  for  biologic  therapy  should  be  screened
for  TB.
.  TB  screening  procedures  should  include  risk  assessment,
evaluation  of  TB  signs  and  symptoms,  chest  radiography,
TST  and  IGRA.
.  After  exclusion  of  active  TB,  the  presence  of  a  positive
TST  (≥10  mm  in  immunocompetent  or  ≥5  mm  in  immuno-
compromised  conditions)  or  positive  IGRA  indicates  the
possibility  of  LTBI  and  LTBI  therapy  should  be  offered.
.  The  existence  of  an  untreated  or  inadequately  treated
previous  TB  (determined  by  chest  X-ray  sequelae  and/or
clinical  history)  should  be  evaluated  for  active  TB
and,  if  that  is  excluded,  LTBI  treatment  should  be
given.
. In  the  event  of  a  recent  exposure  to  a  TB  patient,  LTBI
therapy  should  be  offered,  even  in  the  presence  of  neg-
ative  screening  tests.
. The  recommended  regimen  for  LTBI  treatment  is  9
months  of  isoniazid.
.  Annual  testing  is  recommended  while  on  biological  treat-
ment.
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nexo 1. Protocolo de actuac¸ão para rastreio de doentes candidatos a tratamento
munosupressor.
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